Retina UK

Help us maintain momentum in sight loss research

Inherited retinal conditions are the most common cause of blindness in the working age population of the UK. Last year the first gene therapy for one of these conditions was approved in Europe. This brings real hope; but we must maintain momentum and fund research at this crucial time.

history Campaign has now closed

Donations open 12:00 PM, 3 December 2019 to 12:00 PM, 10 December 2019


Registered Charity in England and Wales (1153851)

Campaign target


Amount raised




Championed by Candis Club

  • Last year we learned our five-year-old son Thomas has Usher syndrome which is slowly impacting his hearing and sight. As a family we fundraise and donate to Retina UK. We hope the research we help fund will one day lead to a treatment for Thomas and others like him.

    — Hannah Baker, mum of Thomas

  • Gene therapy has made huge progress in recent years, bringing with it the very real possibility that inherited sight loss could be stabilised or even cured.

    — Jing Yu, Research Assistant, Nuffield Department of Clinical Neurosciences

  • A huge thank you to supporters of Retina UK who donate time and money. Their generosity allows me to work on my project and pays for essential lab equipment which is critical to gaining new insights into the development and progression of inherited retinal diseases.

    — Jenny Dewing, postdoctoral researcher, University of Southampton


People with inherited sight loss face unique challenges, as they live not only with visual impairment, but also with the knowledge of its inevitable onset and deterioration. Losing your sight can lead to depression, anxiety, social isolation and reduced quality of life, as well as difficulties with finding employment. We aim to do all we can to make these challenges a thing of the past.


We will carefully invest the funds raised into the most promising medical research projects currently taking place. Our selective approach aims to achieve the maximum amount of progress, and the emergence of the very first treatment from the clinical trials pipeline last year evidences the fact that this approach works. The treatment is only for one very specific genetic condition though (RPE65-related LCA), so there is more work to do to ensure that effective treatments are available to all.